×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
LON:EKF

EKF Diagnostics (EKF) Share Forecast, Price & News

GBX 34.50
+0.50 (+1.47%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
34.50
35.40
50-Day Range
33.40
54.20
52-Week Range
33.40
95
Volume
325,637 shs
Average Volume
713,712 shs
Market Capitalization
£156.95 million
P/E Ratio
10.15
Dividend Yield
3.45%
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive EKF News and Ratings via Email

Sign-up to receive the latest news and ratings for EKF Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

EKF Diagnostics logo

About EKF Diagnostics

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical Appliances & Equipment
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
356
Year Founded
N/A

Sales & Book Value

Annual Sales
£81.84 million
Cash Flow
GBX 4.39 per share
Book Value
GBX 20.30 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£156.95 million
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.79 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













EKF Diagnostics (LON:EKF) Frequently Asked Questions

How often does EKF Diagnostics pay dividends? What is the dividend yield for EKF Diagnostics?

EKF Diagnostics announced a dividend on Tuesday, March 29th. Stockholders of record on Thursday, November 3rd will be given a dividend of GBX 1.20 per share on Thursday, December 1st. This represents a dividend yield of 2.35%. The ex-dividend date is Thursday, November 3rd. This is a boost from EKF Diagnostics's previous dividend of GBX 1.10. The official announcement can be viewed at this link.
View EKF Diagnostics' dividend history
.

Is EKF Diagnostics a good dividend stock?

EKF Diagnostics pays an annual dividend of GBX 0.01 per share and currently has a dividend yield of 3.45%. The dividend payout ratio of EKF Diagnostics is 0.32%. This payout ratio is at a healthy, sustainable level, below 75%.
View EKF Diagnostics' dividend history.

Who are EKF Diagnostics' key executives?
EKF Diagnostics' management team includes the following people:
  • Mr. David Michael Salter, CEO & Exec. Director (Age 60)
  • Mr. Marc Peter Davies, CFO & Director (Age 42)
  • Mr. Andrew Webb, Chief Exec. Officer of Ekf Molecular
  • Mr. Salim Hamir F.C.A., Company Sec.
What other stocks do shareholders of EKF Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EKF Diagnostics investors own include ERBA Diagnostics (ERBA), Kirkland Lake Gold (KLG), Telford Homes (TEF), ASOS (ASC), Advanced Computer Software Group (asw), boohoo group (BOO), Newmont (NEM), SolGold (SOLG), Arcontech Group (ARC) and Alliance Pharma (APH).

What is EKF Diagnostics' stock symbol?

EKF Diagnostics trades on the London Stock Exchange (LON) under the ticker symbol "EKF."

How do I buy shares of EKF Diagnostics?

Shares of EKF and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is EKF Diagnostics' stock price today?

One share of EKF stock can currently be purchased for approximately GBX 34.50.

How much money does EKF Diagnostics make?

EKF Diagnostics has a market capitalization of £156.95 million and generates £81.84 million in revenue each year.

How many employees does EKF Diagnostics have?

EKF Diagnostics employs 356 workers across the globe.

What is EKF Diagnostics' official website?

The official website for EKF Diagnostics is www.ekfdiagnostics.com.

How can I contact EKF Diagnostics?

EKF Diagnostics' mailing address is Avon HSE, 19 Stanwell Road, PENARTH, CF64 2EZ, United Kingdom. The company can be reached via phone at +44-29-20710570.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.